AnGes Takes DNA Vaccine Tack As It Enters Virus R&D Fray
Japan Venture Joins Others In Same Approach
Japanese bioventure goes down the DNA vaccine route, along with several others worldwide, pointing to potential development speed and safety advantages.
You may also be interested in...
Efficacy trials are under way and one supplier already has said it would restart production to meet the anticipated demand.
US FDA/NIH smartphone app is intended to allow clinicians and others to talk about potential treatments for infectious diseases, but so far COVID-19-related activity has been limited.
Japan's largest pharma firm has joined the global fray to develop potential therapies for the spreading coronavirus outbreak, focusing initially on its plasma products expertise. But this approach has had some challenges in China.